Table 2.
In vitro activity of ceftazidime in combination with NXL104 versus P. aeruginosa clinical isolates resistant to various antipseudomonal antimicrobials
| P. aeruginosa (no. of isolates) | No. of isolates (cumulative % of all isolates tested) with indicated MIC (μg/ml) |
Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | >16 | ||
| All isolates (470) | 4 (0.9) | 18 (4.7) | 57 (16.8) | 242 (68.3) | 82 (85.7) | 40 (94.3) | 17 (97.9) | 10 (100.0) | 470 |
| Amikacin resistant (29) | 1 (3.4) | 2 (10.3) | 1 (13.8) | 9 (44.8) | 5 (62.1) | 6 (82.8) | 2 (89.7) | 3 (100.0) | 29 |
| Cefepime resistant (29) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (13.8) | 10 (48.3) | 6 (69.0) | 9 (100.0) | 29 |
| Ceftazidime resistant (59) | 0 (0.0) | 1 (1.7) | 0 (1.7) | 6 (11.9) | 15 (37.3) | 17 (66.1) | 10 (83.1) | 10 (100.0) | 59 |
| Ciprofloxacin resistant (96) | 1 (1.0) | 3 (4.2) | 10 (14.6) | 28 (43.8) | 23 (67.7) | 14 (82.3) | 9 (91.7) | 8 (100.0) | 96 |
| Doripenem resistant (70) | 0 (0.0) | 0 (0.0) | 4 (5.7) | 14 (25.7) | 21 (55.7) | 18 (81.4) | 7 (91.4) | 6 (100.0) | 70 |
| Gentamicin resistant (69) | 1 (1.4) | 3 (5.8) | 8 (17.4) | 23 (50.7) | 15 (72.5) | 10 (87.0) | 4 (92.8) | 5 (100.0) | 69 |
| Levofloxacin resistant (112) | 1 (0.9) | 4 (4.5) | 10 (13.4) | 39 (48.2) | 30 (75.0) | 13 (86.6) | 8 (93.8) | 7 (100.0) | 112 |
| Meropenem resistant (32) | 0 (0.0) | 0 (0.0) | 1 (3.1) | 0 (3.1) | 7 (25.0) | 12 (62.5) | 6 (81.3) | 6 (100.0) | 32 |
| Piperacillin-tazobactam resistant (43) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (4.7) | 11 (30.2) | 14 (62.8) | 8 (81.4) | 8 (100.0) | 43 |
| MDR isolates (25) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (24.0) | 9 (60.0) | 5 (80.0) | 5 (100.0) | 25 |